Physician profile
Omar Kousa
NPI 1487133914
$1,143.28
in general payments reported to CMS, 2019-2025
15 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $166 · 2023: $211 · 2024: $223 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $340.57 | 2023-2024 | Cardiomems, Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit |
| Astellas Pharma US INC | $186.99 | 2021-2022 | |
| Edwards Lifesciences Corporation | $126.36 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Boston Scientific Corporation | $78.04 | 2022 | |
| Nuwellis, INC. | $75.24 | 2021 | |
| Merck Sharp & Dohme LLC | $37.46 | 2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $32.30 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $31.25 | 2025 | Repatha, Repatha |
| Medtronic, INC. | $27.33 | 2025 | Linq II |
| Abiomed | $27.14 | 2024 | Impella |
| Pfizer INC. | $18.34 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $17.48 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $13.65 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.13 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Kousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.